Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management

Aug 16, 2025Endocrinology

New Drugs Activating Multiple Hormones for Managing Type 2 Diabetes and Obesity

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Novel dual and triple agonists targeting GLP-1, GIP, glucagon, and GDF15 may improve metabolic parameters in type 2 diabetes mellitus.

Obesity is a primary contributor to insulin resistance, complicating type 2 diabetes management.
Current treatments like SGLT2 inhibitors and GLP-1 receptor agonists are effective but not sufficient for all patients.
Emerging dual and triple agonists are associated with potential improvements in glycemic control and weight management.
These novel agents may also provide cardioprotective and anti-inflammatory benefits.
The safety profiles of these treatments require careful evaluation due to possible adverse effects.

AI simplified

The rising global incidence of type 2 diabetes mellitus and obesity underscores a critical public health challenge, with obesity serving as a primary contributor to insulin resistance. Current treatment modalities, including SGLT2 inhibitors and GLP-1 receptor agonists, have shown efficacy in glycemic control and weight management but remain insufficient for all patients. This review focuses on novel dual and triple agonists targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, and growth differentiation factor 15 (GDF15) due to their emerging clinical importance and recent preclinical progress. Other peptide-based therapies, such as amylin analogs, are beyond the scope of this work and will be addressed in future reviews. Evidence suggests that these novel agents not only improve metabolic parameters but may also offer cardioprotective and anti-inflammatory benefits. While advancements in understanding their mechanisms of action are promising, the safety profiles of these treatments warrant careful evaluation due to potential adverse effects. This review aims to provide a comprehensive overview of the evolving landscape of antidiabetic pharmacotherapy, emphasizing the unique benefits and challenges of emerging agents to optimize clinical outcomes in type 2 diabetes mellitus management.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text ↗

Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief